http://www.fpnotebook.com/
LinezolidAka: Zyvox
- See Also
- Indications
- Vancomycin Resistant Enterococcus
- Nosocomial Pneumonia
- Complicated Skin Infections
- Community Acquired Pneumonia (Not first line agent)
- Does not cover Haemophilus Influenzae
- Methicillin Sensitive Staphylococcus aureus
- Penicillin Sensitive Streptococcus Pneumoniae
- Mechanism
- Prototype for new Oxazolidinone Class
- Inhibits protein synthesis at unique site
- Spectrum
- Minimal activity against Gram Negative Bacteria
- Bacteriostatic activity
- Bactericidal activity
- Pharmacokinetics
- Half Life: 5 hours
- Near 100% bioavailability after oral intake
- Dosing
- Linezolid 400 to 600 mg PO or IV q12 hours
- Administer intravenously over 30 to 120 minutes
- Adverse Effects
- Rash
- Headache
- Diarrhea
- Nausea or Vomiting
- Insomnia
- Constipation
- Fever
- Myelosuppression (requires discontinuation)
- Thrombocytopenia (2.4%)
- Drug Interactions
- No Cytochrome P450 activity or related drug interaction
- Reversible MAO inhibitor (Hypertensive response)
- Do not use with Tyramine Containing Foods
- Avoid with adrenergic drugs
- Avoid concurrent Pseudoephedrine use
- Use caution with concurrent Dopamine or Epinephrine
- Theoretical Serotonin Syndrome
- Not observed in clinical trials
- Use caution with SSRI Antidepressants
- Monitoring: Weekly Complete Blood Count Indications
- Linezolid use longer than 2 weeks
- Preexisting Myelosuppression or risk factors
- Chronic infection on concurrent other antibiotics
- Cost
- Costs $53 to $72 for each oral or intravenous dose
- References
linezolid (C0663241) | |
|---|---|
| Definition (NCI) | A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C098010 |
| English | linezolid, LINEZOLID PREPARATION |
| Spanish | linezolida |
| Parent Concepts | Antibiotics (C0003232), Acetamides (C0000968), Oxazolidinones (C0887953), [AM900] ANTI-INFECTIVES, OTHER (C0973485), Drug allergen (C1320237), Oxazolidinone Antibacterials (C1579350) |
| Sources | LNC, MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Zyvox (C0876226) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C098010 |
| English | Zyvox |
| Sources | MSH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |